Psychotropic medication and the therapeutic community: A survey of prescribing practices for severe personality disorder

Therapeutic Communities

Volumn 25, Issue 2, 2004, Pages 131-144

  Chiesa, Marco ^a   Wright, Miriam ^a   Leger, Delphine ^a  

^a Cassel Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; COCODAMOL; HYPNOTIC AGENT; IBUPROFEN; MOOD STABILIZER; NEUROLEPTIC AGENT; PARACETAMOL; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HUMAN; MALE; PERSONALITY DISORDER; POLYPHARMACY; PRESCRIPTION; PROFESSIONAL STANDARD; PSYCHIATRY; PSYCHOSOCIAL CARE; THERAPEUTIC COMMUNITY; TREATMENT PLANNING;

EID: 4544222070     PISSN: 09641866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bateman, A. W. (1995) The treatment of borderline patients in a day hospital setting, Psychoanalytic Psychotherapy, 9, 3-16.
2. Bazire, S. (1999) Psychotropic Drug Directory 1999: The professional's pocket handbook and aide memoir, Quay Books, Dinton.
3. Bender, D. S., Dolan, R. T., Skodol, A. E., Sanislow, C. A., Dyke, I. R., McGlashan, T. H., Shea, M. T., Zanarini, M. C., Oldham, J. M. and Gunderson, J. G. (2001) Treatment utilization by patients with personality disorders, American Journal of Psychiatry, 158, 295-302.
4. British National Formulary (2003) British Medical Association and British Pharmacological Society.
5. Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M. and Sykora, K. (1986) Withdrawal reaction after long-term use of benzodiazepines, New England Journal of Medicine, 315, 854-859.
6. Cederblad, M. (1996) Fifty years of epidemiologic studies in child and adolescent psychiatry in Sweden, Nordic Journal of Psychiatry, 50, 55-66.
7. Chiesa, M. (1995) Biological and psychic domains: clinical and institutional aspects, Psychoanalytic Psychotherapy, 9, 121-131.
8. Chiesa, M. (1997) A combined inpatient/outpatient programme for severe personality disorders, Therapeutic Communities, 18, 297-309.
9. Chiesa, M., Bateman, A., Wiberg, T. and Friis, S. (2002) Patients characteristics, outcome and cost-benefit of hospital-based treatment for patients with personality disorder: A comparison of three treatment programmes, Psychology and Psychotherapy, 75: 381-393
10. Chiesa, M. and Fonagy, P. (2000) Cassel personality disorder study: methodology and treatment effects, British Journal of Psychiatry, 176, 485-491.
11. Chiesa, M. and Fonagy, P. (2003) Psychosocial treatment of personality disorder study. 36-months follow-up, British Journal of Psychiatry, 183, 356-362.
12. Chiesa, M., Fonagy, P., Holmes, J. and Drahorad, C. (2004) Residential versus community treatment of personality disorder: A comparative study of three treatment programs, American Journal of Psychiatry, 61: 1463-1470.
13. Coccaro, E. and Kavoussi, R. J. (1997) Fluoxetine and impulsive aggressive behaviour in personality disorder, Archives of General Psychiatry, 54, 1081-1088.
14. Day, L. and Flynn, D. (2003) Mind and Body: Therapeutic work with children and adolescents, Karnac Books, London.
15. Fava, G. A. (2003) Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of Clinical Psychiatry, 64, 123-133.
16. Friis, S., Wilberg, T., Dammen, T. and Urnes, ÿ. (1999) Pharmacotherapy for patients with personality disorders, In Treatment of Personality Disorders (Eds, Derksen, J., Maffei, C. and Groen, H.) Plenum Books, London, pp. 255-268.
17. Griffiths, P. and Leach, G. (1998) Psychosocial nursing: A model learned from experience, In Face to Face with Distress: The Professional Use of Self in Psychosocial Care (Eds, Barnes, E., Griffiths, P., Ord, J. and Wells, D.) Butterworth Heinemann, Oxford, pp. 5-41.
18. Harrington, M., Lelliot, P., Paton, C., Okocha, C., Duffett, R. and Sensky, T. (2002) The results of a multi-centre audit of the prescribing of anti-psychotic drugs for in-patients in the UK, Psychiatric Bulletin, 26, 414-418.
19. Healy, K., Kennedy, R. and Sinclair, J. (1991) Child physical abuse observed: Comparison of families with and without a history of child abuse treated in an in-patient family unit, British Journal of Psychiatry, 158, 234-237.
20. Hinshelwood, R. D. and Skogstad, W. (1998) The hospital in the mind: In-patient psychotherapy at the Cassel Hospital, In Psychoanalytic Psychotherapy in Institutional Settings (Eds, Pestalozzi, J., Frisch, S., Hinshelwood, R. D. and Houzel, D.) Karnac Books, London, pp. 59-73.
21. Jones, M. (1956) The concept of the therapeutic community, American Journal of Psychiatry, 112, 647-650.
22. Kennedy, R. (1997) Child Abuse, Psychotherapy and the Law, Free Associations Books, London.
23. Koenigsberg, H. W. (1994) The combination of psychotherapy and pharmacotherapy in the treatment of borderline personality disorder, Journal of Psychotherapy Practice and Research, 3, 93-107.
24. Lader, M. (1989) Benzodiazepine dependence, International Review of Psychiatry, 1, 149-156.
25. Lader, M. and File, S. (1987) The biological basis of benzodiazepine dependence, Psychological Medicine, 17, 539-546.
26. Marcus, E. (1990) Integrating psychopharmacotherapy, psychotherapy and mental structure in the treatment of patients with personality disorders and depression, Psychiatric Clinics of North America, 13, 255-263.
27. NIMH(E) (2003) Personality disorder: No longer a diagnosis of exclusion, Department of Health.
28. Norton, K. (1992) Personality disordered individuals: The Henderson Hospital model of treatment, Criminal Behaviour and Mental Health, 2, 180-191.
29. Rapaport, R. N. (1960) Community as doctor: new perspectives on a therapeutic community, Tavistock Publishing, London.
30. Silk, K. R., Lohr, N. E., Westen, D. and Goodrich, S. (1989) Psychosis in borderline patients with depression, Journal of Personality Disorders, 3, 92-100.
31. Soloff, P. H. (1993) Pharmacological therapies in borderline personality disorder, In Borderline personality disorder: Etiology and treatment (Ed, Paris) American Psychiatric Press, Washington DC, pp. 319-348.
32. Soloff, P. H. (2000) Psychopharmacology of borderline personality disorder, Psychiatric Clinics of North America, 23, 169-192.
33. Spitzer, R. L., Williams, J., Gibbon, M. and First, M. (1990) Structured Clinical Interview for DSM-III-R, American Psychiatric Press, Washington DC.
34. The Royal College of Psychiatrists (1997) The association between antipsychotic drugs and sudden death, London, The Royal College of Psychiatrists, January 1997 CR57
35. Tyrer, P. (1989) Risks of dependence on benzodiazepine drugs: the importance of patient selection, British Medical Journal, 298, 102-105.
36. Tyrer, P. (2000) Personality Disorders. Diagnosis, Management and Course, Butterworth Heiman, Oxford.
37. Wallerstein, R. S. (1988) Assessment of structural change in psychoanalytic therapy and research, Journal of the American Psychoanalytic Association, 36, Supplement.
38. Warren, F., Preedy-Fayers, K., McGauley, G., Pickering, A., Norton, K., Geddes, J. R. and Dolan, B. (2003) Review of Treatments for Severe Personality Disorder, London, Home Office Online Publication, www.homeoffice.gov.uk/rds/onlinepubs1.htlm
39. World Health Organization (1992) ICD-10: Classification of Mental and Behavioural Disorders, WHO, Geneva.
40. Zanarini, M. C. and Frankenburg, F. R. (2001) Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo controlled pilot study, Journal of Clinical Psychiatry, 62, 849-854.
41. Zanarini, M. C., Frankenburg, F. R., Khera, G. S. and Bleichmar, J. (2001) Treatment histories of borderline inpatients, Comprehensive Psychiatry, 42, 144-150.